Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L34 pseudogene 35 (RPL34P35) is a pseudogene in humans, related by sequence similarity to the functional ribosomal protein L34 gene (RPL34), which encodes a structural constituent of the large (60S) ribosomal subunit involved in protein synthesis. Pseudogenes like RPL34P35 are typically non-functional, meaning they do not encode functional proteins; instead, they are genomic DNA sequences similar to functional genes but are generally considered transcriptionally inactive, lacking an active biological role. RPL34P35, along with many other processed ribosomal protein pseudogenes, is dispersed across the human genome and primarily serves as a genomic landmark of evolutionary history rather than as an active molecular target[1][7][5][4]. Context & Interpretation: - RPL34P35 is specifically identified as a pseudogene, not as a protein-coding gene or an active receptor, enzyme, transporter, or other therapeutic drug target[1][7]. - No evidence indicates a direct role in disease, active biological function, clinical biomarker utility, drug interaction, or mechanism of action. All such roles pertain to its functional counterpart, ribosomal protein L34 (RPL34)[5][4]. - Its naming conventions and aliases follow typical numbering in the processed ribosomal pseudogene family[7]. - No functional, pharmacological, or clinical data are available for this entity, because this is common for ribosomal protein pseudogenes, which do not encode functional proteins in the human genome[1][5][4]. If you need information about the functional ribosomal protein L34 (RPL34), let me know for details on its molecular classifications, roles in ribosome structure/function, and disease associations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 35 (RPL34P35).